Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Eisai Inc., Exelixis, Inc., and Prometheus Laboratories Inc.
Medical Crossfire®: Crossroads in Advanced RCC Decision-Making: With Many Options, How Will You Treat Your Patient Today?... And Tomorrow?
Medical Crossfire®: Crossroads in Advanced RCC Decision-Making: With Many Options, How Will You Treat Your Patient Today?... And Tomorrow? is a case-based, interactive, live symposium to be held adjunct to the 2019 Genitourinary Cancers Symposium in San Francisco. Clinical decision-making in the setting of metastatic renal cell carcinoma (mRCC) has been undergoing dramatic change. The approval of new systemic agents has expanded the lines of therapy available to patients, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in RCC.
The unique format of this educational program features a review of the most recent and practically relevant data and best practices, along with lively debate and discussion between faculty and attendees regarding clinical challenges and questions faced in daily practice. For example: On what factors should you base treatment selection? What will be the optimal next-line therapy for patients who have received a frontline immunotherapy-tyrosine kinase inhibitor combination? What is the role of local therapy in the modern era?
Please join us for this dynamic educational activity designed to help you apply evidence-based, state-of-the-art management strategies to your practice.
This educational program is directed toward all attendees of the Genitourinary Cancers Symposium, including medical oncologists, surgical oncologists, radiation oncologists, and urologists involved in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with RCC are also invited to participate.
Upon completion of this activity, participants should be able to:
- Explain the biologic factors that drive renal cell carcinoma (RCC) that provides the rationale for using targeted agents and immunotherapies, as single agents and in combination
- Evaluate practice-changing and emerging data from RCC clinical trials across the advanced disease continuum
- Apply best practices to proactively identify and mitigate treatment-related toxicities related to therapy for metastatic RCC
- Integrate knowledge of patient characteristics, as well as the efficacy and safety of single-agent and combination systemic therapies, into clinical decision-making for patients with metastatic RCC
Acknowledgment of Commercial Support
This activity is supported by educational grants from Eisai Inc, Exelixis, Inc., and Prometheus Laboratories Inc.
Toni K. Choueiri, MD
Director, the Lank center for Genitourinary Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
You must be logged in to PER to register for this meeting
Or Register for PER now